BMS-986365

· Celgene (part of Bristol Myers Squibb)

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for BMS-986365, covering 2025-03-06 to 2026-01-28. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer [Phase 3]

See pricing